Alpha RegistryClaim a profile
Published mark

Amphastar Pharmaceuticals, Inc.

NASDAQ: AMPH. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:380224c7-eafa-4d64-9d0c-7f061a379958
SEC CIK
0001297184
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 18, 2026
Newest evidence
May 3, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Jack Yongfeng ZhangSince Apr 13, 2026
Chair
Not published
Independent
7 / 1111 directors published
Published claims
343 distinct sources
Evidence records
100 pinned
Source conflicts
0None open

Built from 3 distinct sources and 10 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

CEO CHANGED

Jack Yongfeng Zhang executive of Amphastar Pharmaceuticals, Inc., effective 2026-04-13.

EffectiveEffective Apr 13, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Executive Officer, President, Chief Scientific Officer and DirectorJack Yongfeng ZhangApr 2026currentSource reportedE3
Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary and DirectorJacob LiawatidewiApr 2026currentSource reportedE5
Chief Operating Officer, Chief Scientist and Chairman of the Board of DirectorsMary Ziping LuoApr 2026currentSource reportedE6
Senior Executive Vice President of Production Center; Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.Rong ZhouApr 2026currentSource reportedE8
Chief Financial Officer, Executive Vice President of Finance, and Treasurer; President of International Medication Systems, Limited and DirectorWilliam J. PetersApr 2026currentSource reportedE9
Chief Executive Officer, President, Chief Scientific Officer and DirectorJack Yongfeng Zhang, Ph.DNot capturedunknownSource reportedE4
Chief Operating Officer, Chief Scientist and Chairman of the Board of DirectorsMary Ziping Luo, Ph.DNot capturedunknownSource reportedE7

Board of directors

Evidence

11 directors published. 7 of 11 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
David GaughIndependent2025CompensationSource reportedE2
Diane G. GerstIndependent2019Nominating and Governance, chairNominating and Governance · ChairSource reportedE2
Floyd F. PetersenIndependent2004CompensationSource reportedE2
Gayle DeflinIndependent2021Audit, chairAudit · ChairSource reportedE2
Hsin-Liang LeeIndependent2008AuditAudit; Nominating and GovernanceNominating and GovernanceSource reportedE2
Jacob LiawatidewiNot independent2022None publishedSource reportedE2
Jun ZhangNot independent1996None publishedSource reportedE2
Mary Ziping LuoNot independent1996None publishedSource reportedE2
Michael A. ZasloffIndependent2005CompensationCompensation; Nominating and GovernanceNominating and GovernanceSource reportedE2
Richard PrinsIndependent2002Compensation, chairCompensation · ChairSource reportedE2
William J. PetersNot independent2022None publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditGayle DeflinGayle Deflin, Hsin-Liang LeeNot described in the published record
Audit · ChairNot publishedGayle DeflinNot described in the published record
Audit; Nominating and GovernanceNot publishedHsin-Liang LeeNot described in the published record
CompensationRichard PrinsRichard Prins, David Gaugh, Floyd F. Petersen, Michael A. ZasloffNot described in the published record
Compensation · ChairNot publishedRichard PrinsNot described in the published record
Compensation; Nominating and GovernanceNot publishedMichael A. ZasloffNot described in the published record
Nominating and GovernanceDiane G. GerstDiane G. Gerst, Hsin-Liang Lee, Michael A. ZasloffNot described in the published record
Nominating and Governance · ChairNot publishedDiane G. GerstNot described in the published record
Committee RecordAudit: Chair Gayle Deflin; Members Gayle Deflin (Chair); Hsin-Liang Lee
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_record:23
Committee AppointmentGayle Deflin: chair, Audit
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:24
Committee AppointmentHsin-Liang Lee: member, Audit
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:25
Committee RecordCompensation: Chair Richard Prins; Members Richard Prins (Chair); David Gaugh; Floyd F. Petersen; Michael A. Zasloff
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_record:26
Committee AppointmentRichard Prins: chair, Compensation
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:27
Committee AppointmentDavid Gaugh: member, Compensation
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:28
Committee AppointmentFloyd F. Petersen: member, Compensation
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:29
Committee AppointmentMichael A. Zasloff: member, Compensation
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:30
Committee RecordNominating and Governance: Chair Diane G. Gerst; Members Diane G. Gerst (Chair); Hsin-Liang Lee; Michael A. Zasloff
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_record:31
Committee AppointmentDiane G. Gerst: chair, Nominating and Governance
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:32
Committee AppointmentHsin-Liang Lee: member, Nominating and Governance
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:33
Committee AppointmentMichael A. Zasloff: member, Nominating and Governance
Source reportedE10
company:380224c7-eafa-4d64-9d0c-7f061a379958:committee_appointment:34

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerJack Yongfeng Zhang, Chief Executive Officer, President, Chief Scientific Officer and Director, from Apr 13, 2026
Source reportedE3
company:380224c7-eafa-4d64-9d0c-7f061a379958:leadership_role:16
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingAMPH (NASDAQ)
Source reportedE1
company:380224c7-eafa-4d64-9d0c-7f061a379958:security_listing:35
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 18, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameAmphastar Pharmaceuticals, Inc.
Source reportedE1
company:380224c7-eafa-4d64-9d0c-7f061a379958:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:380224c7-eafa-4d64-9d0c-7f061a379958:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
10 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 18, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    Amphastar Pharmaceuticals, Inc. DEF 14A 2026-04-13
    sec proxy. Published Apr 13, 2026. Retrieved Apr 24, 2026. Cited by 11 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    AMPH DEF 14A executive officers
    sec filing. Published Apr 13, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    AMPH executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    AMPH DEF 14A executive officers
    sec filing. Published Apr 13, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    AMPH DEF 14A executive officers
    sec filing. Published Apr 13, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    AMPH executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    AMPH DEF 14A executive officers
    sec filing. Published Apr 13, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    AMPH DEF 14A executive officers
    sec filing. Published Apr 13, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    Audit
    board_seats. board seats. Cited by 12 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 18, 2026
  • Jack Yongfeng Zhang executive of Amphastar Pharmaceuticals, Inc., effective 2026-04-13.
  • Jacob Liawatidewi executive of Amphastar Pharmaceuticals, Inc., effective 2026-04-13.
  • Mary Ziping Luo executive of Amphastar Pharmaceuticals, Inc., effective 2026-04-13.
  • Rong Zhou executive of Amphastar Pharmaceuticals, Inc., effective 2026-04-13.
  • William J. Peters executive of Amphastar Pharmaceuticals, Inc., effective 2026-04-13.
  • David Gaugh seat on Amphastar Pharmaceuticals, Inc., effective 2025-01-01.
  • David Gaugh member of Compensation, effective 2025-01-01.
  • Jacob Liawatidewi seat on Amphastar Pharmaceuticals, Inc., effective 2022-01-01.
  • William J. Peters seat on Amphastar Pharmaceuticals, Inc., effective 2022-01-01.
  • Gayle Deflin seat on Amphastar Pharmaceuticals, Inc., effective 2021-01-01.
  • Audit · Chair committee of Amphastar Pharmaceuticals, Inc., effective 2021-01-01.
  • Gayle Deflin member of Audit · Chair, effective 2021-01-01.
  • Diane G. Gerst seat on Amphastar Pharmaceuticals, Inc., effective 2019-01-01.
  • Nominating and Governance · Chair committee of Amphastar Pharmaceuticals, Inc., effective 2019-01-01.
  • Diane G. Gerst member of Nominating and Governance · Chair, effective 2019-01-01.
  • Hsin-Liang Lee seat on Amphastar Pharmaceuticals, Inc., effective 2008-01-01.
  • Audit; Nominating and Governance committee of Amphastar Pharmaceuticals, Inc., effective 2008-01-01.
  • Hsin-Liang Lee member of Audit; Nominating and Governance, effective 2008-01-01.
  • Michael A. Zasloff seat on Amphastar Pharmaceuticals, Inc., effective 2005-01-01.
  • Compensation; Nominating and Governance committee of Amphastar Pharmaceuticals, Inc., effective 2005-01-01.
  • Michael A. Zasloff member of Compensation; Nominating and Governance, effective 2005-01-01.
  • Floyd F. Petersen seat on Amphastar Pharmaceuticals, Inc., effective 2004-01-01.
  • Richard Prins seat on Amphastar Pharmaceuticals, Inc., effective 2002-01-01.
  • Compensation · Chair committee of Amphastar Pharmaceuticals, Inc., effective 2002-01-01.
  • Richard Prins member of Compensation · Chair, effective 2002-01-01.
  • Jun Zhang seat on Amphastar Pharmaceuticals, Inc., effective 1996-01-01.
  • Mary Ziping Luo seat on Amphastar Pharmaceuticals, Inc., effective 1996-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:380224c7-eafa-4d64-9d0c-7f061a379958, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/amphastar-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership7
  4. Board11
  5. Committees8
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people18
  17. Subject and corrections6
  18. Evidence10
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:380224c7-eafa-4d64-9d0c-7f061a379958
  • Cite this recordAmphastar Pharmaceuticals, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/amphastar-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Amphastar Pharmaceuticals, Inc.Company
  • Jack Yongfeng ZhangPerson
  • Jacob LiawatidewiPerson
  • Mary Ziping LuoPerson
  • Rong ZhouPerson
  • William J. PetersPerson
  • Jack Yongfeng Zhang, Ph.DPerson
  • Mary Ziping Luo, Ph.DPerson
  • David GaughPerson
  • Diane G. GerstPerson
  • Floyd F. PetersenPerson
  • Gayle DeflinPerson
  • Hsin-Liang LeePerson
  • Jacob LiawatidewiPerson
  • Jun ZhangPerson
  • Mary Ziping LuoPerson
  • Michael A. ZasloffPerson
  • Richard PrinsPerson
  • William J. PetersPerson
  • Sections
    OverviewAmphastar Pharmaceuticals, Inc.
  • MonitoringAmphastar Pharmaceuticals, Inc.
  • LeadershipAmphastar Pharmaceuticals, Inc.
  • BoardAmphastar Pharmaceuticals, Inc.
  • CommitteesAmphastar Pharmaceuticals, Inc.
  • Control and votingAmphastar Pharmaceuticals, Inc.
  • Authority to actAmphastar Pharmaceuticals, Inc.
  • FinancialsAmphastar Pharmaceuticals, Inc.
  • GovernanceAmphastar Pharmaceuticals, Inc.
  • RiskAmphastar Pharmaceuticals, Inc.
  • AI oversightAmphastar Pharmaceuticals, Inc.
  • LegalAmphastar Pharmaceuticals, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.